Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Sodium butyrate (HB1399)
Description:HDAC inhibitor. Directs mESC differentiation into hepatocytes.
Splitomicin (HB4091)
Description:Potent,selective, cell permeable yeast NAD+-dependent HDAC Sir2p inhibitor
Purity:>98%
Trichostatin A (HB1402)
Description:Potent HDAC inhibitor. Induces hiPSCs differentiation to cardiogenic cells and induces accelerated dedifferentiation of primordial germ cells.
Purity:>98%
Valproic acid sodium salt (HB0867)
Description:Histone deacetylase inhibitor. Shows multitude of biological actions. Enables pluripotent stem cell induction from somatic cells.